{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:16:56Z","timestamp":1795209416044,"version":"4.10.3"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clinre.2026.102760","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:23:54Z","timestamp":1767659034000},"page":"102760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction\u2013associated steatohepatitis (MASH): A real-world data analysis"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3472-013X","authenticated-orcid":false,"given":"Elizabeth","family":"Beyene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Chirumamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekdem","family":"Bisrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Fetle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Wilkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addishiwot","family":"Wudeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Fahad","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Larbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinre.2026.102760_bib0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction\u2013associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102760_bib0002","first-page":"1","article-title":"Comprehensive review on non-alcoholic fatty liver disease (NAFLD): clinical advancement and drug treatments","volume":"1","author":"Sahu","year":"2024","journal-title":"Prob Sci"},{"issue":"22","key":"10.1016\/j.clinre.2026.102760_bib0003","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clinre.2026.102760_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102760_bib0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.clinre.2026.102760_bib0006","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"NN9931-4296 investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"10019","key":"10.1016\/j.clinre.2026.102760_bib0007","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clinre.2026.102760_bib0008","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.clinre.2026.102760_bib0009","first-page":"2219","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"20","author":"Shimizu","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.clinre.2026.102760_bib0010","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"NN9931-4296 investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clinre.2026.102760_bib0011","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.clinre.2026.102760_bib0012","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.clinre.2026.102760_bib0013","first-page":"576","article-title":"Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a randomized, open-label pilot study (ToPiND study)","volume":"50","author":"Ozaki","year":"2020","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.clinre.2026.102760_bib0014","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium\u2013glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"8","key":"10.1016\/j.clinre.2026.102760_bib0015","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","article-title":"Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice","volume":"22","author":"Yamamoto","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"16","key":"10.1016\/j.clinre.2026.102760_bib0016","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.clinre.2026.102760_bib0017","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/pharmaceutics17081036","article-title":"Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base","volume":"17","author":"Patel","year":"2025","journal-title":"Pharmaceutics"},{"issue":"22","key":"10.1016\/j.clinre.2026.102760_bib0018","first-page":"2819","article-title":"Mechanisms of sodium\u2013glucose cotransporter 2 inhibition: insights from large-scale proteomics","volume":"75","author":"Ferrannini","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102760_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2025.102584","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): exploring systemic impacts and innovative therapies","volume":"49","author":"Jain","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102760_bib0020","first-page":"2433","article-title":"Current trends in the treatment of hepatocellular carcinoma: clinical applications and advancement","volume":"1","author":"Sinha","year":"2024","journal-title":"Prob Sci"},{"issue":"7","key":"10.1016\/j.clinre.2026.102760_bib0021","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4254\/wjh.v13.i7.763","article-title":"Racial differences in prevalence and severity of non-alcoholic fatty liver disease","volume":"13","author":"Bonacini","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2026.102760_bib0022","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142024. Diabetes Care. 2024;47(Suppl 1):S1\u2013S191. https:\/\/doi.org\/10.2337\/dc24-SINT.","DOI":"10.2337\/dc24-SINT"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:37:24Z","timestamp":1770237444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2210740126000070"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102760","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction\u2013associated steatohepatitis (MASH): A real-world data analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102760"}}